

# Information for Prescribers of Prescription Drugs Provided Pursuant to Colorado HB 19-1131 and Connecticut HB 6669

## ELOCTATE® [Antihemophilic factor (recombinant), Fc fusion protein]

| <u>Marketed Prescription Drug</u> | <u>WAC* Price</u> |
|-----------------------------------|-------------------|
| Eloctate 250 Unit Nominal         | \$ 2.68 per IU    |
| Eloctate 500 Unit Nominal         | \$ 2.68 per IU    |
| Eloctate 750 Unit Nominal         | \$ 2.68 per IU    |
| Eloctate 1,000 Unit Nominal       | \$ 2.68 per IU    |
| Eloctate 1,500 Unit Nominal       | \$ 2.68 per IU    |
| Eloctate 2,000 Unit Nominal       | \$ 2.68 per IU    |
| Eloctate 3,000 Unit Nominal       | \$ 2.68 per IU    |
| Eloctate 4,000 Unit Nominal       | \$ 2.68 per IU    |
| Eloctate 5,000 Unit Nominal       | \$ 2.68 per IU    |
| Eloctate 6,000 Unit Nominal       | \$ 2.68 per IU    |

Your patients' out of pocket cost may be different

### Below please find as applicable three generic prescription drugs\*\*

none

Information on the variation efficacy of the legend (prescribed) drug marketed to different racial and ethnic groups, if such information is available, can be found in the drug's FDA approved Prescribing Information document which can be accessed at <https://www.sanofi.us/en/products-and-resources/prescription-products>.

**\*Wholesale Acquisition Cost (WAC)** as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

For more information about First Databank's drug pricing policy, visit <https://www.fdbhealth.com/drug-pricing-policy>

**\*\*The USC (Uniform System of Classification) Therapeutic Classification** schema was used to determine similar generic drugs. The **HCFA Drug Category of "Non-Innovator Multi-source"** as supplied on the CMS (formerly HCFA) quarterly update was used to determine the generic status of the drug products. This list does not imply that the generic prescription drugs on this form are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.